salflumix easyhaler 50 mikrog / 250 mikrog / annos inhalaatiojauhe
orion corporation - fluticasone propionate, salmeterol xinafoate - inhalaatiojauhe - 50 mikrog / 250 mikrog / annos - salmeteroli ja flutikasoni
salflumix easyhaler 50 mikrog / 500 mikrog / annos inhalaatiojauhe
orion corporation - fluticasone propionate, salmeterol xinafoate - inhalaatiojauhe - 50 mikrog / 500 mikrog / annos - salmeteroli ja flutikasoni
budesonide stada 0.25 mg/ml sumutinsuspensio
stada arzneimittel ag - budesonide - sumutinsuspensio - 0.25 mg/ml - budesonidi
budesonide stada 0.5 mg/ml sumutinsuspensio
stada arzneimittel ag - budesonide - sumutinsuspensio - 0.5 mg/ml - budesonidi
salmeterol/fluticasone neutec 50 mikrog / 100 mikrog / annos inhalaatiojauhe, annosteltu
neutec inhaler ireland limited - fluticasone propionate, salmeterol xinafoate - inhalaatiojauhe, annosteltu - 50 mikrog / 100 mikrog / annos - salmeteroli ja flutikasoni
salmeterol/fluticasone neutec 50 mikrog / 250 mikrog / annos inhalaatiojauhe, annosteltu
neutec inhaler ireland limited - fluticasone propionate, salmeterol xinafoate - inhalaatiojauhe, annosteltu - 50 mikrog / 250 mikrog / annos - salmeteroli ja flutikasoni
salmeterol/fluticasone neutec 50 mikrog / 500 mikrog / annos inhalaatiojauhe, annosteltu
neutec inhaler ireland limited - fluticasone propionate, salmeterol xinafoate - inhalaatiojauhe, annosteltu - 50 mikrog / 500 mikrog / annos - salmeteroli ja flutikasoni
polivy
roche registration gmbh - polatuzumab vedotin - lymfooma, b-solu - antineoplastiset aineet - polivy yhdessä bendamustiinin ja rituksimabi on tarkoitettu aikuisille potilaille, joilla oli uusiutunut/vaikeahoitoinen hajanainen suuri b-solu lymfooma (dlbcl), jotka eivät ole ehdokkaita vertamuodostavan kudoksen kantasolujen siirto. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
serefarm 50 mikrog / 500 mikrog /annos inhalaatiojauhe, annosteltu
orifarm generics a/s - fluticasone propionate, salmeterol xinafoate - inhalaatiojauhe, annosteltu - 50 mikrog / 500 mikrog /annos - salmeteroli ja flutikasoni